Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC vs Dose-Dense MVAC in Adjuvant Urothelial Carcinoma
NCT01639521Phase 2Withdrawn
- Sponsor
- University of Southern California
- Start
- May 2013
- Primary completion
- May 2013
- Modality
- Targeted Liposomes, Orthosteric Ligands, Stealth (PEGylated) Liposomes
01
Overview
Phase 2, randomised, open-label trial of gemcitabine, Cisplatin micelle injection (HA132), methotrexate, vinblastine and pegylated liposomal doxorubicin in urothelial carcinoma (UC) (2 arms), sponsored by University of Southern California. Primary endpoint: Rate of unacceptable toxicity at 3 years. Planned start May 2013; status: withdrawn.
02
Drugs
gemcitabineCisplatin micelle injection (HA132)methotrexatevinblastinepegylated liposomal doxorubicin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT01639521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01639521.